

# State of Illinois Drugs and Therapeutics Advisory Board

## Minutes for April 6, 2023 Meeting

- I. Dr. Patel opened the meeting at 8:30 am
- II. Roll Call was taken. Dr. Florence was excused from attendance. A quorum was established.
- III. No conflicts of Interest
- IV. The January 12, 2023 meeting minutes were unanimously approved.
- V. Public Testimony was presented as below:

<b>Speaker</b>	<b>Product</b>	<b>Organization</b>
Frank J. Palella Jr. MD	Sunlenca	Gilead
Chase Williams, PharmD, MBA, AAHIVE	Sunlenca	Gilead
Bobbi Bentz, Associate Director, Health Outcomes Liaison	Emgality	Lilly
Jasmine Inman, PharmD	Ajovy	Teva
Lori Blackner, PharmD	Zavegepant/Nurtec	Pfizer
Neelesh Nadkarni, PharmD, MSPH	Qulipta/Ubrelvy	AbbVie
Kenneth Berry	Lybalvi	Alkermes
Margaret Martin, PharmD	Caplyta	IntraCellular Therapies
William Puga, MD	Caplyta	IntraCellular Therapies
Roueen Rafeyan, MD	Caplyta	IntraCellular Therapies
Lynn Lochner, APRN-FNP-BC, PMHNP-BC	Rexulti	Otsuka
Arden Arslanyan, PharmD	Rexulti	Otsuka
Karen Nguyen	Vraylar	AbbVie

- VI. There are no PDL Drug Appeals for this meeting.
  - VII. New Drug Appeals.
    - a. Perseris (manufacturer was unavailable to provide comment) Ryan Rodriguez, PharmD gave a summary of the product
      - Risperidone long acting subQ formulation
      - Schizophrenia indication in adults
- Discussion Highlights
- Open access to all long-acting injectables was advocated
- Motion: Dr. Vergara-Rodriguez moves to make Persis preferred with PA  
Second: Dr. Berkowitz  
The motion passes with Dr. Patel abstaining.

## VIII. Class Reviews

- a. Topic: Oral Atypical Antipsychotics  
Presented by: Ryan Rodriguez, PharmD

### Presented Material Highlights:

- Indications for the products were discussed
- Call out of those products with multiple indications
- Newer agents have different receptor binding profiles than some of the older agents, but no comparative studies have been done
- Newer agents tend to have fewer indications than the older agents
- APA 2020 Guidelines state that for schizophrenia no single agent is best as product should be chosen for the specific patient
- Some studies show that clozapine and olanzapine are likely most effective for schizophrenia
- Adverse event profiles differ and should be considered in choosing an agent
- Bipolar guidelines are more specific
  - Bipolar with mania-1<sup>st</sup> line quetiapine, asenapine, aripiprazole, paliperidone, risperidone and cariprazine
  - Bipolar with depression-1<sup>st</sup> line quetiapine or lurasidone
    - Boxed warnings include metabolic complications

### Discussion Highlights:

- Discussed preferred and non-preferred with possible change in lurasidone and paliperidone status
- MCOs support making lurasidone preferred
- Discussed the merits of the newer brand name products
- Metabolic issue was very heavily discussed
- Discussed make Preferred with PA products require no more than 2 prior failures
- Experience may suggest that oral atypical antipsychotics are used for many mood disorders
- Discussed moving some older products to non-preferred since they are no longer used as often

Motion: Dr. Berkowitz moved to make lurasidone preferred

Second: Dr. Vergara-Rodriguez

Motion passed without dissent

Motion: Dr. Vergara-Rodriguez moved to make Rexulti preferred with PA

Second: Dr. Berkowitz

Motion passed without dissent

Motion: Dr. Berkowitz moved to make Vraylar preferred with PA

Second: Dr. Vergara-Rodriguez

Motion passed without dissent

Motion: Dr. Vergara-Rodriguez moved to make Caplyta preferred with PA

Second: Dr. Berkowitz

Motion passed without dissent

Motion: Garry Moreland moved to review some of the older products for relevance at a later date

Second: Dr. Vergara-Rodriguez

Motion passed with Dr. Berkowitz abstaining

b. Topic: CGRP Migraine Agents

Presented by: Ryan Rodriguez, PharmD

Presented Material Highlights:

- The America Headache Society position state in 2021 categorizes products with established efficacy versus probable efficacy
- All products in this class, except for the two newest agents are considered established
- Initiation of the CGRPs is recommended after failure of at least two other treatments or intolerance to those treatments
- There are some safety issues to consider prior to initiation

Discussion Highlights:

- Discussion on which products are self-administered
- All are self-administered except Vyepi
- Discussed that there are no current deficiencies on the PDL as is
- Emgality is also approved for cluster headaches

Motion: Dr. Patel moved that Emgality be moved from non-preferred to preferred with PA

Second: Dr. Albers

Motion passed with Dr. Goyal abstaining

IX. New Drug Initial Reviews

a. Product: Tzield

Presented by: Ryan Rodriguez, PharmD

Presented Material Highlights:

- Indicated to delay the onset of Type 1 diabetes in patients 8 years and older
- Diagnosis and initiation could be prior to symptom appearance
- Prolongs the time of diagnosis and symptoms by 2 years
- Safety signals include Cytokine release Syndrome and serious infection
- Administered once daily for 14 days

Discussion Highlights:

- Interest in the fact that it is for delay on onset

- Usually only standard of care for patients with a family member that has Type 1 diabetes
- Discussion to wait to see the demand and further research before moving PDL status

Motion: Dr. Patel moved to have Tzielid remain non-preferred

Second: Dr. Goyal

Motion passed without dissent.

- b. Product: Briumvi  
Presented by: Ryan Rodriguez, PharmD

Presented Material Highlights:

- Indicated for adults with relapsing MS
- CD20 mechanism like Ocrevus and Kesimpta
- Given every 6 months IV
- Not yet considered in the guidelines

Discussion Highlights:

- No discussion

Motion: Dr. Patel moved to leave Briumvi non-preferred.

Second: Garry Moreland

Motion passed with no dissent.

- c. Product: Sunlenca  
Presented by: Ryan Rodriguez, PharmD

Presented Material Highlights:

- Indicated for heavily experienced patients with an optimized background regimen
- On the guidelines as a novel agent for use in resistant populations

Discussion Highlights:

- These are used very rarely
- Rarely see these agents used
- Benefit is very high for the right patient
- Much easier to give than Trogarzo which is currently preferred with PA
- Want to see Trogarzo moved to non-preferred

Motion: Dr. Vergara-Rodriguez moved Sunlenca be preferred with a PA

Second: Dr. Albers

Motion passed with no dissent

- X. Provider Review Request  
Presented by: Sheri Dolan, BSPharma

- a. Oral Albuterol Syrup-A group of providers requested this be made non-preferred because it has been removed from national guidelines after being found to be less effective than inhalant Albuterol and have more side effects.
- Presented approved indications for oral Albuterol syrup
  - Presented the department utilization data
  - Proposed that the department would reach out with education to providers still using oral Albuterol where inhalers would be more effective

Discussion:

- Board surprised oral is still available

Motion: Dr. Patel moved to make oral Albuterol syrup non-preferred

Second: Dr. Albright

Motion passed with no dissent

- b. Removal of the Prior Approval requirement for Hep C Products
- The Department proposed that the prior approval be removed from the currently preferred with PA Hep C products to broaden access to these products.
  - The Department prefers that the D&T Advisory Board make this decision.
  - Dr. Goyal explained the timeline and the current criteria and the reason for it.
  - The Department would require 1 hour of CME in Hep C in order for non-specialists to prescribe.
  - Concern was expressed around prescribing without knowing the side effects and drug interactions possible.
  - The Department would make CME available on the honor system.
  - Rural physicians need this opportunity.
  - This is needed for certain hard to reach populations.
  - The Department will make a CME course available on the webpage and would support any other programs.
  - MCOs do still see denials for good reason.
  - Some of the details will still need to be worked out.

Motion: Dr. Goyal motioned that the currently preferred with PA Hep C products be preferred when prescribed by a

primary care physician after completion of a 1-hour CME to educate on the intricacies of prescribing these drugs

Second: Garry Moreland

Motion passed with no dissent

- XI. Future Agenda Preview-Sheri Dolan shared the proposed calendar for 2023 meetings as below:

July 13, 2023-Sickle Cell Disease

October 12, 2023-Blood Glucose Products

- XII. Department Update-no report.

- XIII. Adjournment-Dr. Patel adjured the meeting at 11:06 am

## Attendees

The names of board members and speakers are bolded.

### Panelist List

1. Alyssa Stephenson
2. Sheri Dolan
3. **Deborah Albright**
4. **Cynthia VanSteenburg**
5. Donna Clay
6. **Arvind Goyal**
7. Claudia Colombo
8. **Garry Moreland**
9. Ryan Rodriguez
10. **Maurice Shaw**
11. **Janet Albers**
12. Heather Freeman
13. Lori Uildriks
14. Jose Jimenez
15. **Pamela Vergara-Rodriguez**
16. Jennifer Dewitt
17. Mary Moody
18. **Mahesh Patel**
19. **Paul Berkowitz**

### Attendee List

1. **Arden Arslanyan**
2. **Bobbi Bentz**
3. Brad Mullens
4. Brandi Shannon
5. Brooks, Kimbra
6. Bryan
7. Call in User 3
8. Call in User 5
9. Call in User 6
10. Call in User 7
11. Call in User 9
12. Call in User 10
13. **Chase Williams**
14. Cindy Pennington
15. Clemice Hurst

16. Dan Skoubye
17. Dani Mendez
18. Daphne Ni
19. Doug A Johnson
- 20. Frank Palella**
21. Gary Parenteau
22. Huzefa Master
23. James Sharp
- 24. Jasmine Inman**
25. Jeff Knappen
26. Jen
27. Jen Tamburo
28. Jenny Phone
29. John Bullard
30. Justin Simmons
31. Karen Finn
- 32. Karen Nguyen**
33. Keith O'Hara
34. Kelly
35. Kelly Draveling
36. Kelly Petrowski
37. Ken Hammonds
- 38. Kenneth Berry**
39. Leanne Shu
- 40. Lori Blackner**
- 41. Lynn Lochner**
- 42. Margaret Martin**
43. Mary Kaneaster
44. Mark Friederich
45. Michele Shirley-Indivior
46. Mike Krug
- 47. Neelesh Nadkarni**
48. Patty Minear
49. Phil Lohec
50. PL
51. Rebecca Kaucki
52. Robert Baldrige
53. Robert Pearce
- 54. Roueen Rafeyan**
55. Sakib Hassan
56. Sara Geo
57. Shauna Williams
58. Shawn Fairweather
59. Stacey Repotski

60. Steve Hiemenz
61. Steve Patterson
62. Sujal Patel
63. Swarup Mehta
64. Tammy Bima
65. Thomas Dorn
66. Thomas Vayalil
67. Tiawana Parker
68. Tina Costianis
69. Waleed Al-Homoud
70. Yvonne
71. Zhen